Technologies

Aliophen-XP is a highly concentrated polyphenolic composition derived from Aliophen®, a patented formulation based on malt and hops (Patent No. 102017000096298). Developed to enhance the original formulation, Aliophen-XP is produced through a specialized process that removes components potentially interfering with the biological activity of the bioactive compounds naturally extracted from malt and hops.

Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL)  and a purity, at least equal to food/cosmetic grade (P≥2).

The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.

The procedure enables the fabrication of nanocomposite membranes filled with suitable amounts of exfoliated bidimensional crystals. These are obtained with an advanced wet-jet milling technique, which provides desired thickness and lateral size of nanofillers through the pulverization and colloidal homogenization of bulk nanomaterials. The bidimensional crystals are dispersed in fluids and suitably delivered inside polymeric matrixes exhibiting a singular morphology.

This invention comprises an interrogation and readout differential method for chemical sensors based on Surface Plasmon Resonances (SPR). The integration of the SPR sensing unit (chip or other), as intermediate reflecting element of a Fabry-Perot (FP) optical resonator, is the starting point for the application of this method.

The systems simulate, with high reproducibility, the conditions that occur in the different compartments of the gastrointestinal tracts and are promising to accurately mimic the digestive process, with the possibility to evaluate bioaccessibility and bioavailability. Moreover, the systems permit to study the synergic and reciprocal effects between the bioactive compounds characteristic of food and intestinal microbiota.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules: